SUTRO BIOPHARMA - Key Persons

Job Titles:

• Director of the Judy

Dr. Krishnan is the Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope in Duarte, CA. She is also Associate Director, Medical Education & Training Program, Department of Hematology & Hematopoietic at City of Hope. She is board certified in Hematology and Medical Oncology and serves as Attending Physician at City of Hope Comprehensive Cancer Center. Dr. Krishnan received her B.S (Cum Laude, Phi Beta Kappa) from Union College in Schenectady, NY and her medical degree from Albany Medical College as part of an accelerated six year medical program where she was inducted into the AOA medical honor society. She completed her residency in Medicine at University of Rochester and fellowship in Hematology/Oncology at New England Deaconess Hospital and Dana Farber Cancer Institute at Harvard Medical School. Her primary research interests include multiple myeloma and has participated in over 50 clinical studies as an individual or principal investigator. Dr. Krishnan's research has been published in numerous medical journals including Blood, Lancet Oncology and New England Journal of Medicine.

Job Titles:

• Member of the Clinical Advisory Board
• Head of the Gynecological Tumor Unit

Dr. Oaknin is the Head of the Gynecological Tumor Unit and full-time Senior Attending Physician at Medical Oncology Department at the Vall d'Hebron University Hospital in Barcelona, as well as the Principal Clinical Investigator of the Gynecological Malignancies Group at the Vall d'Hebrón Institute of Oncology. She also leads the Gynecological Cancer program at the Baselga Institute of Oncology. Dr. Oaknin received her Degree in Medicine and Surgery from the Universidad Complutense of Madrid and her Ph.D. from the Universidad Autonoma de Barcelona. She is the Principal Investigator on several clinical trials in ovarian, cervical, and endometrial cancer and has authored over 100 publications and presentations. Dr. Oaknin is an executive board member and Co-Chair of the GEICO Group (Spanish Ovarian Cancer Research Group) and an active member of the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), and the Spanish Association of Medical Oncology (SEOM).

Job Titles:

• Member of the Scientific Advisory Board
• Chairman, Scientific Advisory Board

Carlos Paya, M.D., Ph.D. is currently the Senior Advisor at Abingworth Ventures, Chair, Board of Directors at Fluidigm and Highlight Therapeutics since 2020 and Board member at BIO, Fluidigm and Mallinckrodt. Dr. Paya received his M.D. and Ph.D. from the University Complutense, Madrid, Spain. Followed by his post-doctoral training in viral immunology from Institute Pasteur, Paris, France. U.S. Board certified in Internal Medicine & Infectious Diseases from the Mayo Graduate School, Rochester, MN. During his time at Mayo Medical School, Dr. Paya was the Professor of Medicine, Immunology, and Pathology. He made numerous scientific contributions to the fields of cell biology and viral immunology and to the clinical field of immune-comprised patients; supported by multiple NIH and industry grants. Elected to the American Society of Clinical Investigation and Editorial Boards of prestigious scientific journals, NIH study sections and Collaborative Groups. Author of over 200 peer-reviewed articles. Dr. Paya's track record as senior executive in large-cap pharma, mid-cap and start-up biotech companies. During his 8 years at Immune Design, he was CEO and President, and member of the Board. Immune Design was acquired by Merck (May 2019).

Job Titles:

• Chairman of the Board of Directors
• Member of the Nominating and Governance Committee
• Science and Technology

Connie Matsui has served as a member, and Chair, of our Board of Directors since June 2019 and brings over three decades of general management experience in the biotechnology industry. From 2004 to 2009, Ms. Matsui served in various leadership positions at Biogen Idec, Inc., including as Executive Vice President, Knowledge and Innovation Networks and Executive Committee member. Prior to that, Ms. Matsui served in various leadership positions at IDEC Pharmaceuticals, a predecessor of Biogen Idec, including Senior Vice President; Collaboration Chair for the late stage development and commercialization of rituximab (tradenames: Rituxan® and MabThera®) in partnership with Roche and Genentech; and Project Leader for Zevalin®, the first radioimmunotherapy approved by the U.S. FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui currently serves on the boards of directors of Halozyme Therapeutics, Inc. and Artelo Biosciences, Inc., and has served on not-for-profit boards at the local, national and global level. Ms. Matsui received a B.A. and an M.B.A. from Stanford University. We believe that Ms. Matsui is qualified to serve on our Board of Directors because of her strong biotechnology managerial and commercial experience, including her expertise with biopharmaceutical product development, sales and marketing, corporate strategy and operations.

Job Titles:

• Member of the Board of Directors
• Member of the Compensation Committee
• Member of the Nominating and Governance Committee
• Compensation
• Member of Our Board of Directors

Daniel H. Petree, has served as a member of our Board of Directors since August 2009. In April 2012, Mr. Petree co-founded Four Oaks Partners Consulting, LLC, which provides transaction advisory services to small and medium-sized life science companies and in 2000, Mr. Petree co-founded P2 Partners, LLC, Four Oaks' predecessor in the same business. Before co-founding P2 Partners, Mr. Petree served as President and Chief Operating Officer of Axys Pharmaceuticals, Inc., Executive Vice President and Chief Financial Officer of Arris Pharmaceuticals, Incorporated and Vice President of Business Development at TSI Corporation and was a corporate and securities lawyer. Mr. Petree previously served on the boards of directors of Lpath, Inc., Biocept, Inc. and Cypress Bioscience, Inc. along with a number of privately held biotechnology companies. Mr. Petree received an A.B. in History and Political Science from Stanford University and a J.D. from the University of Michigan Law School. We believe that Mr. Petree is qualified to serve on our Board of Directors because of his experience in the biotechnology industry, including structuring and negotiating pharmaceutical partnering arrangements and strategic transactions.

Job Titles:

• General Counsel

Mr. Pauling joined Sutro in 2011 and has since held positions of increasing responsibility, including Intellectual Property Counsel, Associate General and Senior Intellectual Property Counsel, and most recently Executive Director of Legal Affairs. Prior to joining Sutro, Mr. Pauling practiced law at Jones Day and at Pennie & Edmonds, LLP. Mr. Pauling received his J.D. from Santa Clara University School of Law (magna cum laude), and an M.A. in Molecular Biology and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.

Job Titles:

• Chief Medical Officer
• Business Executive, Scientific Advisor and Board Director
• CMO, Business Executive, Scientific Advisor and Board Director

Dr. Anne Borgman is an accomplished CMO, business executive, scientific advisor and board director with 20+ years of experience devising clinical development strategies and successfully leading teams to excellence and timely execution in oncology-hematology drug approvals. Dr. Borgman's strength lies in her ability to organize and galvanize teams to fulfil mission critical business objectives. She is a creative problem solver and developer of human capital. Her broad network, depth of regulatory interactions and experience developing oncology and hematology drugs enables her to quickly synthesize the competitive landscape and collaborate with key stakeholders to forge a strategic path forward in a complex landscape. Dr. Borgman has led teams to successful approval of several oncology assets. Most recently while Therapeutic Area Head Hematology-Oncology and Vice President at Jazz Pharmaceuticals, she led a successful filing for a recombinant asparaginase using the intensive Real Time Oncology Review process and expanded filings for other hematology-oncology assets. Prior, while Vice President at Exelixis, Inc. she led several successful filings for the lead asset cabozantinib, including a U.S. and European approval in renal cell carcinoma, a U.S. and European approval in hepatocellular carcinoma and a European approval in medullary thyroid carcinoma. Additionally, Dr. Borgman led the filing for an accelerated approval for liposomal vincristine in adult relapsed acute lymphoblastic lymphoma while Chief Medical Officer at Hana Biosciences. Dr. Borgman created the early development strategies for the Bcl-2/Bcl-XL inhibitor (now venetoclax) and veliparib while Global Project Head for Abbott Laboratories. In addition to her strong core competency in hematology oncology drug development, she has led companies through growth phases at every stage in her career. Her ability to build strong partnerships across the healthcare sector, both internally and externally, has delivered proven results throughout her career, with patient benefit at the center. She serves on the Board of Directors of NextCure, Inc., a biotechnology company at the nexus of immuno-oncology and targeted therapies, Curis, a biotechnology company focused on targeted therapies for AML, and NiKang, a privately owned clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines. She is an active mentor and passionate about cancer treatment, as evidenced by her role on the advisory boards of Healthcare Businesswomen's Association (HBA), Y-ME National Breast Cancer Association, Bear Necessities Pediatric Cancer Foundation, CureSearch for Children's Cancers, and prior volunteer faculty positions in pediatric hematology oncology and stem cell transplant at both the University of Chicago Comer Children's Hospital and Lucile Packard Children's Hospital Stanford. She uses her knowledge, energy and engaging style to facilitate awareness, connect and innovate. Dr. Borgman received an M.D. from Loyola University Chicago Stritch School of Medicine. She received a BS degree in Biochemistry from University of Illinois, Urbana-Champaign. Dr. Borgman completed a Residency in Pediatrics from Baylor College of Medicine in Houston, Texas and a Fellowship in Pediatric Hematology-Oncology and Bone Marrow Transplantation from the David Geffen School of Medicine at UCLA. In addition, Dr. Borgman is a graduate of the Stanford Executive Program and an alumni of Stanford University's Graduate School of Business.

Job Titles:

• Member of the Clinical Advisory Board
• Member of the Scientific Advisory Board
• Co - Chair, Clinical Advisory Board
• Medical Oncologist

Lawrence Fong, MD, is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at UCSF. He also co-directs the Parker Institute for Cancer Immunotherapy at UCSF and co-leads the Cancer Immunology Program in the Helen Diller Family Comprehensive Cancer Center. Dr Fong will serve as Co-Chair of Sutro's Clinical Advisory Board and will also participate as a member of Sutro's Scientific Advisory Board in his capacity as Co-Chair of the CAB. Dr. Lawrence Fong is a medical oncologist who specializes in immunotherapy to care for cancer patients with an emphasis on genitourinary cancers (those involving the genital or urinary organs). A physician-scientist, Dr. Fong studies new immunotherapies for cancer. He is internationally known for his work on multiple FDA-approved cancer immunotherapies including sipuleucel-T and immune checkpoint inhibitors. He has helped conduct numerous clinical trials and is the principal investigator on multiple research projects including those supported by the National Institutes of Health and private foundations. As the leader of UCSF's Cancer Immunotherapy Program, he helps to develop new treatments through early-phase clinical trials of novel immunotherapies. His laboratory focuses on understanding why current treatments work in some patients but not others. Throughout his career, Dr. Fong has received several awards for his scientific contributions, including the National Cancer Institute's Outstanding Investigator Award. Dr. Fong earned his medical degree at Stanford University. He completed a residency in internal medicine at the University of Washington. He completed an oncology fellowship at Stanford Medicine. Dr. Fong joined the UCSF faculty in 2001 and is the Efim Guzik Distinguished Professor in Cancer Biology. He has published more than 100 peer-reviewed scientific articles, numerous book chapters, and multiple patents. Dr. Fong has lectured nationally and internationally on cancer immunotherapy.

Job Titles:

• Chief Financial Officer

Edward Albini has served as our Chief Financial Officer since January 2013. During 2012, Mr. Albini served as a consulting Chief Financial Officer for Carbylan Biosurgery, a company focused on the development and commercialization of advanced biomaterial-based joint therapies. From 2011 to 2016, Mr. Albini also served as Chief Financial Officer and Secretary for Itero Holdings, LLC, a successor entity to Itero Biopharmaceuticals, Inc., a company focused on the development and commercialization of protein therapeutics, at which Mr. Albini served as Chief Financial Officer and Senior Vice President from 2009 to 2011. Previously, Mr. Albini served as Chief Financial Officer of Novacea, Inc. and Lynx Therapeutics, Inc., both biopharmaceutical companies. Mr. Albini received a B.S.C. in Accounting from Santa Clara University and an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley. Mr. Albini is also a certified public accountant (inactive status) in California.

Job Titles:

• Investor Relations and Communications Advisor

Job Titles:

• Chief Scientific Officer
• Executive
• Co - Founder of Codeable Therapeutics

Hans-Peter Gerber is a seasoned executive with over 25 years of experience in oncology drug development, including antibody-drug conjugates (ADCs), redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies (TCR-T and CAR-T cells). He has built and led highly successful drug development teams in pharma, biotech, and startup companies and oversaw the preclinical development of therapeutic programs in oncology, from target identification to IND filings. Hans-Peter is the co-founder of Codeable Therapeutics, an ADC startup company focusing on the development of next-generation ADCs that induce immunogenic cell death. He also serves as independent board member at Athebio, a startup company located in Basel, Switzerland developing the next generation of Darpin biotherapeutics and as Chairman of the Board at T-CURX, a startup company located in Wuerzburg, Germany, dedicated to the development of next-generation CAR-T cell therapies. From 2018 to 2022, Hans-Peter served as CSO and SVP of 3T Biosciences, where he built up the research organization to over 30 FTEs. He oversaw target identification, platform- and preclinical program development of TCR-T cell and CD3-bispecific programs targeting pHLA complexes. He completed an series A round as interim CEO in June 2021. Between 2017 and 2021, he served as an independent director on the board of NBE Therapeutics, a clinical-stage ADC company located in Basel, Switzerland, which was acquired by Boehringer Ingelheim in Q1/21. From 2016 to 2018, he built up the R&D organization at Maverick Therapeutics to 25 FTEs as President and CSO in the context of a "build to buy" collaboration with Takeda. Takeda exercised its option to acquire Maverick in Q1/21, after the Maverick team successfully filed two INDs for conditional CD3-bispecifics. Prior to his recent roles in startup Biotechs, Hans-Peter held leadership positions at several top biopharmaceutical companies, including Genentech, Seattle Genetics, and Pfizer, where he led the R&D group in Pearl River, NY, as CSO. During this time, he oversaw the development of multiple oncology biotherapeutic programs and modalities, from discovery through IND filings. He oversaw the development of novel, site specific ADC platforms with various linker and payloads and bispecific compounds redirecting T-cell to tumors. His teams contributed to three BLAs, including Avastin and two ADCs (Mylotarg, Besponsa), and he led the filing of over ten INDs for ADCs and bispecifics, several of which are currently undergoing late-stage clinical trials. Hans-Peter is an author on over 100 peer-reviewed papers and reviews in high-impact journals and a co-inventor on over 100 issued patents. He received an MS in Biochemistry and a PhD in Molecular Biology from the University of Zurich, Switzerland.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Audit / Science and Technology
• Member of Science and Technology Committee

Heidi Hunter has over 25 years of experience in biotech across the pharmaceutical value chain, from clinical and commercial development through to launch execution. She is formerly President at Cardinal Health, where she lead the Specialty Solutions Businesses. Prior to Cardinal Health, Ms. Hunter was Senior Vice President of the Global Immunology Business Unit at UCB in Brussels. She has also held leadership positions at Boehringer Ingelheim as Senior Vice President and General Manager in its Global Biosimilars Business, and at IQVIA as Vice President of Global Business Partnerships Commercial Solutions. Ms. Hunter also held senior leadership positions in commercial and strategic marketing for biologics and oncology at Centocor, a J&J company. She also led women's health and oncology business at Wyeth (today part of Pfizer) in the U.S. and women's health at Novo Nordisk in Denmark. Early in Ms. Hunter's career, she led sales and marketing at Wyeth and led Neurology at Ciba-Geigy in Switzerland (today part of Novartis). She is currently on the board of Vicore Pharma, Bavarian Nordic and IO Biotech. Ms. Hunter earned B.A. from The University of Michigan and her M.B.A. from The University of Chicago.

Job Titles:

• Independent Consultant
• Member of the Board of Directors
• Member of the Nominating and Governance Committee
• Member of Our Board of Directors
• Member of Science and Technology Committee
• Nominating and Governance / Science and Technology

James Panek has served as a member of our Board of Directors since January 2020. Since 2011, Mr. Panek has served as an Independent Consultant for various biopharmaceutical companies, and currently serves as Acting COO and Director for CHO Plus, a privately owned biotechnology company. From 2010 to 2011, Mr. Panek served as interim President, Chief Executive Officer and Principal Financial Officer at DiaDexus, Inc. From 2007 to 2010, Mr. Panek served as President, Chief Executive Officer and Principal Financial Officer for VaxGen, Inc., now a subsidiary of DiaDexus, Inc. From 2002 to 2006, Mr. Panek served as Senior and Executive Vice President of VaxGen, Inc., and Co-Chief Executive Officer and Chairman of the Board for Celltrion Inc., then a VaxGen manufacturing joint venture in Inchon, Korea. In his role with Celltrion, Mr. Panek was responsible for the development and FDA licensure of the first large scale biopharmaceutical manufacturing facility in Asia. From 1982 to 2001, Mr. Panek served in various capacities with Genentech, Inc., including Senior Vice President, Product Operations, and Vice President, Manufacturing, Engineering and Facilities, where he led the development of the world's largest biotechnology manufacturing facility and was responsible for all operations involved in supplying products for preclinical, clinical, and commercial use. Prior to joining Genentech, Mr. Panek spent six years with Eli Lilly in a variety of engineering and development positions. Mr. Panek previously served on the boards of directors of DiaDexus, Inc., VaxGen, Inc. and Celltrion Inc. Mr. Panek received a B.S. and an M.S. in Chemical Engineering from the University of Michigan. We believe that Mr. Panek is qualified to serve on our board of directors due to his extensive experience in operations, engineering, manufacturing and product development.

Job Titles:

• Chief Operating Officer
• President

Jane Chung, RPh has over 20 years of pharmaceutical and biotechnology experience and serves as our President and Chief Operating Officer since December 2023 and previously our Chief Commercial Officer since August 2021. From 2015 to 2021, Ms. Chung served in several leadership roles at AstraZeneca, including as President and General Manager of AstraZeneca Canada, Vice President of Sales and Marketing of U.S. lmmuno-Oncology, and Senior Commercial Business Director. Prior to that, from 2013 to 2015, Ms. Chung served as a Regional Sales Director and Director of Sales Productivity and Effectiveness for Onyx Pharmaceuticals Inc. From 2003 to 2013, she served in various commercial roles for Genentech, Inc., including as Commercial Operations Manager, Division Manager and Senior Marketing Manager. Ms. Chung also serves on the Board of Directors of Viracta Therapeutics, Inc. and on non-profit boards in the science, education, and community development arenas. Ms. Chung received her B.A. from Columbia University, New York, and B.S. in Pharmacy from St. John's University, New York.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Audit

John G. Freund, M.D., has served as a member of our Board of Directors since February 2014. Dr. Freund founded Skyline Ventures, a venture capital firm, in September 1997, where he served as a Managing Director. Prior to founding Skyline, Dr. Freund served as Managing Director at Chancellor Capital Management, co-founded Intuitive Surgical, Inc. (NASDAQ - ISRG), served in various positions at Acuson Corporation, most recently Executive Vice President, was a general partner at Morgan Stanley Venture Partners and co-founded the Healthcare Group in the Corporate Finance Department of Morgan Stanley. In addition, in 2016 Dr. Freund co-founded and was CEO of Arixa Pharmaceuticals, Inc. an antibiotic company, which was acquired by Pfizer in 2020. Dr. Freund currently serves on the boards of directors of Collegium Pharmaceutical, Inc., SI Bone, Inc. and a number of U.S. registered investment funds managed by affiliates of Capital Group, Inc. Dr. Freund is a founding member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund previously served on the boards of directors of several publicly traded companies, including Proteon Therapeutics, Inc., XenoPort, Inc., where he was Chairman, Concert Pharmaceuticals, Inc., Tetraphase Pharmaceuticals, Inc., MAP Pharmaceuticals, Inc. and MAKO Surgical Corp. Dr. Freund received an A.B. in History from Harvard College, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School, where he was a Baker Scholar. We believe that Dr. Freund is qualified to serve on our Board of Directors because of his training as a physician and his extensive investment, business and board experience with public healthcare and biopharmaceutical companies.

Job Titles:

• Member of the Clinical Advisory Board

Dr. Leonard is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Associate Dean for Clinical Research at Weill Cornell Medicine and Vice Chairman of the Weill Department of Medicine. He has board certifications in Hematology and Medical Oncology and serves as Attending Physician at Weill Cornell Medicine and New York Presbyterian Hospital. Dr. Leonard received his undergraduate degree from Johns Hopkins University and his medical degree from the University of Virginia School of Medicine. He completed his residency in Medicine at New York Hospital - Cornell Medical Center/Memorial Sloan-Kettering Cancer Center and fellowship in Hematology-Oncology at New York Presbyterian Hospital - Cornell Medical Center. His primary research interests include novel therapeutic strategies for the treatment of lymphoma and related hematologic malignancies, and has participated in over 50 clinical studies as an individual or principal investigator. Dr. Leonard's research has been published in numerous medical journals, and he has served as a member of the editorial boards of Blood and Journal of Clinical Oncology. He is the Lymphoma Committee Chair of the Alliance for Clinical Trials in Oncology, a National Cancer Institute-supported cooperative group in the National Clinical Trials Network.

Job Titles:

• Member of the Board of Directors
• Member of the Compensation Committee
• Physician
• Scientist
• Compensation
• Member of Science and Technology Committee

Dr. Wigginton is a physician and scientist with expertise in oncology drug development. He has over 25 years of experience in clinical oncology, with leadership experience in both academia and industry. Dr. Wigginton currently serves as President, Research and Development at Bright Peak Therapeutics. Most recently, he was Senior Advisor and Chairman of the SAB at Cullinan Oncology, Inc., having served previously as the Chief Medical Officer. Prior, he was Chief Medical Officer at MacroGenics, where he led the company's clinical development programs. Dr. Wigginton also held leadership positions at Bristol Myers Squibb as Therapeutic Area Head in Immuno-Oncology for Early Clinical Research and as Executive Medical Director and Group Medical Director of Discovery Medicine-Clinical Oncology, and prior to that, Director of Clinical Oncology at Merck & Co. Dr. Wigginton has also served in several positions for the Society for Immunotherapy of Cancer (SITC), including President, Chair of Executive Council, Board of Directors, and leadership roles on various operating committees. Early in his career, Dr. Wigginton worked at the National Cancer Institute for over 14 years and served as Head of the Investigational Biologics Section in the Center for Cancer Research (intramural program). Dr. Wigginton earned his M.D. from the University of Michigan.

Job Titles:

• Member of the Audit Committee
• Member of the Board of Directors
• Member of the Compensation Committee
• Audit
• Member of Our Board of Directors

Joseph M. Lobacki has served as a member of our Board of Directors since February 2017. From January 2020 to January 2024, Mr. Lobacki served as President and CEO of Artax a private biopharmaceutical company developing treatments for autoimmune and inflammatory diseases focused on modulating the T-Cell Receptor response to antigen stimulation. Since January 2024, Mr. Lobacki has served in an advisory role at Artax, and as an independent consultant to Biotech companies. Previously, Mr. Lobacki served as Executive Vice President and Chief Commercial Officer for Verastem, Inc., a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of hematologic malignancies. From November 2016 to December 2017, Mr. Lobacki served as Chief Operating Officer for Crestovo, a clinical-stage biopharmaceutical company focused on microbiome therapies. From 2014 to 2016, Mr. Lobacki served as Chief Commercial Officer at Medivation, Inc., a biopharmaceutical company focused on development of novel therapies for the treatment of serious diseases. From 2012 to 2014, Mr. Lobacki also served as General Manager of Oncology and an independent biotechnology consultant at Idera Pharmaceuticals, Inc., a biopharmaceutical company focused on therapies for cancer and rare diseases. Previously, Mr. Lobacki served as Senior Vice-President and Chief Commercial Officer at Micromet, Inc., Senior Vice-President and General Manager of US Transplant and Oncology at Genzyme Corporation and in various other positions at SangStat Medical Corporation, Cell Pathways, Inc., Rhone-Poulenc Rorer and Lederle Laboratories. Mr. Lobacki previously served on the board of directors of Celator Pharmaceuticals Inc. Mr. Lobacki received a B.S. in Biology from Boston College and a B.S. in Pharmacy from the Massachusetts College of Pharmacy. We believe that Mr. Lobacki is qualified to serve on our Board of Directors because of his strong biopharmaceutical managerial and commercial experience, including his expertise with biopharmaceutical research and development, sales and marketing and strategy and operations.

Job Titles:

• Medical Oncologist
• Member of the Clinical Advisory Board

Dr. Martin is a medical oncologist specializing in the treatment of gynecologic cancers. She spent 15 years at the Fox Chase Cancer Center where she led the Gynecologic Research Program and served as the interim Physician Director of the Office of Clinical Research as well as co-chair of the Scientific Review Committee. She was recruited to the University of Pennsylvania to serve as the Leader of the Gynecologic Medical Oncology Program. She is an Associate Professor in the department of Hematology/Oncology at the University of Pennsylvania and serves as the Associate Director of the Gynecologic Oncology Clinical Research Unit. She has served as the Principal or Site Principal Investigator on over 75 trials and has extensive experience in the design and management of Phase I, II and III clinical trials.

Job Titles:

• Chief People and Communications Officer

Linda Fitzpatrick has served as our Chief People and Communications Officer since August 2018. From January 2008 to August 2018, Ms. Fitzpatrick served as our VP of Human Resources and Communications in the capacity of Senior Advisor. In addition to her strategic consulting practice, she co-founded Parallax Venture Partners, an early stage health care venture fund in April 2002. From October 1992 to March 2002, Ms. Fitzpatrick served as Vice President of Human Resources, Corporate Communications and Operations for Gilead Sciences, Inc. and from February 1985 to September 1992 she served as Director of Investor Relations and Director of Compensation, Benefits and Systems for Genentech, Inc., in addition to heading the human resources and corporate communications strategy for a variety of publicly held biotechnology companies. Ms. Fitzpatrick also serves on a variety of non-profit boards, including board chair roles, in the science, education and community development arenas. Ms. Fitzpatrick received a B.A. in Psychology and Sociology from San Francisco State University.

Job Titles:

• Chairman
• Member of the Board of Directors
• Member of Science and Technology Committee
• Partner at Samsara BioCapital

Michael Dybbs, Ph.D., has served as a member of our Board of Directors since July 2018. Dr. Dybbs is currently a partner at Samsara BioCapital, where he has worked since March 2017. Prior to joining Samsara, Dr. Dybbs was a partner at New Leaf Venture Partners, where he worked from May 2009 until September 2016. Before joining New Leaf Venture Partners, L.L.C., Dr. Dybbs was a principal at the Boston Consulting Group. Dr. Dybbs currently serves on the boards of directors of Nkarta and several private companies. Dr. Dybbs previously served on the boards of directors of Versartis, Inc. and Dimension Therapeutics, Inc. Dr. Dybbs received an A.B. in biochemical sciences from Harvard College and a Ph.D. in molecular biology from University of California, Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. We believe that Dr. Dybbs is qualified to serve on our Board of Directors due to his experience in the life sciences industry and the venture capital industry, and his leadership and management experience.

Job Titles:

• Chief Portfolio Strategy & Alliance Officer

Dr. Vasquez has more than 25 years of biopharmaceutical discovery research and development experience and has lead our alliance and portfolio management since 2015. Prior to joining Sutro, she was Vice President of Program & Portfolio Management at StemCells, Inc., where she was responsible for establishing project management of research and clinical stage programs exploring neuronal stem cell therapy for Alzheimer's Disease, spinal cord injury and dry AMD. Prior to that she was at Elan, where she held positions of increasing responsibility from Alzheimer's Disease and autoimmune discovery research, to Vice President Research Operations & Program Management, and Vice President Development Program & Portfolio Management. Dr. Vasquez obtained her doctoral degree in immunology from the University of California, San Diego, and received her post-doctoral training at Genentech. Dr. Vasquez serves on the Board of Directors for Actinogen Medical and was honored as one of Fierce Pharma 2021 Fiercest Women in Life Sciences. Click the link to read the article, https://www.fiercepharma.com/special-report/women-life-sciences-2021?oly_enc_id=8908A7445778A3R

Job Titles:

• Member of the Clinical Advisory Board
• Professor & Director of Gynecologic Oncology Research

Dr. Naumann is currently Professor & Director of Gynecologic Oncology Research and Associate Medical Director of Clinical Trials at the Levine Cancer Institute, Atrium Health. He did his residency in Obstetrics and Gynecology and fellowship in Gynecologic Oncology at the University of Alabama School of Medicine in Birmingham. He has served as a board member on the Executive Council of the Society of Gynecologic Oncology (SGO) and the Chair of Education Committee and was a co-director of the SGO Winter meeting. Dr. Nauman has an interest in chemotherapy development including targeted therapies and immune therapies and runs the phase I trials in gynecologic oncology at the Levine Cancer Institute. He has served as a member of the GOG/NRG corpus committee and the Developmental Therapeutics committee.

Job Titles:

• Member of the Scientific Advisory Board
• Executive Vice President and Head of Cancer Biology and Target Discovery at Odyssey Therapeutics

Robert Abraham, Ph.D., is Executive Vice President and Head of Cancer Biology and Target Discovery at Odyssey Therapeutics. Prior to joining Odyssey, he was the Chief Scientific Officer at Vividion Therapeutics. He is also an Adjunct Professor at the Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI) and Adjunct Professor in the Department of Pharmacology at the University of California-San Diego. Dr. Abraham received his B.S. from Bucknell University and his Ph.D. from the University of Pittsburgh, followed by post-doctoral training in both Pharmacology and Immunology at the Mayo Clinic. Dr. Abraham remained at the Mayo Clinic, where held academic positions as a Professor in the Department of Immunology and the Department of Pharmacology, and as Director of Basic Sciences in the Mayo Comprehensive Cancer Center. He then joined the faculty at the Duke University Medical Center, where he served as a Professor in the Department of Pharmacology and Cancer Biology and as the Associate Director of Translational Research in the Duke Comprehensive Cancer Center. Next, Dr. Abraham was a Professor at SBPMDI, where he founded the Signal Transduction Research Program and served as the Director of the NCI-designated SBPMDI Cancer Research Center. Dr. Abraham then transitioned from academia to industry, as Vice President of Oncology Research at Wyeth Discovery Research and later as Senior Vice President and Group Head of the Oncology R&D Group in Pfizer Worldwide Research, Development and Medical. He also was the founding Director of the Pfizer Postdoctoral Research Program. Throughout his career, Dr. Abraham has received several awards for his scientific contributions, including the Legacy Laureate Award as an outstanding alumnus of the University of Pittsburgh. He is the author of over 225 scientific publications and has served on and chaired grant review panels at the National Institutes of Health.

Job Titles:

• Consultant
• Member of the Scientific Advisory Board

Dr. Frankel was most recently Chief Medical Officer at Cytovia. Previously, he was the Senior Vice President, Cellular Therapy Development at Bristol-Myers Squibb (BMS) where he was responsible for late development portfolio of cellular therapy assets including Breyanzi® and Abecma®. While at BMS, he sat on multiple leadership teams and committees, including the Global Drug Development Leadership Team and the Cell Therapy Commercial Steering Committee. Prior to the BMS acquisition of Celgene, he was Corporate Vice President, Head, Immuno-Oncology & Cellular Therapy, Clinical Research and Development Head, Cell Therapy Clinical Center of Excellence. While at Celgene he co-chaired the Hematology-Oncology Development Committee and served on the Hematology-Oncology Franchise Leadership Team. He served on Joint Steering and/or Joint Development Committees for alliances with JW Therapeutics, Jounce Therapeutics, Astra-Zeneca/Medimmune, Juno Therapeutics, and BeiGene. Dr. Frankel is a consultant and serves as an independent member of the Board of Directors for Myeloid Therapeutics and a member of Scientific Advisory Boards for Adagene, Immunai, and Sutro Biopharma. Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University, and has been a board-certified licensed physician since 1986. He completed his residency in internal medicine at Mount Sinai Hospital and his fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center where he was Chief Fellow. He has prior academic and clinical appointments at Roswell Park Cancer Institute, Georgetown University, and the University of Maryland prior to joining Columbia University Vagelos College of Physicians and Surgeons as Adjunct Associate Professor of Medicine in the Division of Hematology/Oncology.

Job Titles:

• Member of the Scientific Advisory Board

Trevor J. Hallam, Ph.D., is currently CSO of Laronde, a private biotech company designing and developing a new class of translatable circular "endless" RNA modalities that are capable of addressing a wide range of therapeutic needs that have been underserved by the limitations of current drug design. Dr Hallam served as Sutro's Chief Scientific Officer from December 2010 to May 2023, where he led the strategic focus of the company's technology development into precision design of complex conjugated biologics. During his tenure 6 novel therapeutics progressed into clinical development. He was promoted to President, Research and CSO in 2021. Prior to joining us, Dr. Hallam was Executive Vice President of Research & Development at Palatin Technologies, Inc., and held several senior management positions in various pharmaceutical companies, including AstraZeneca PLC, Roche, Glaxo and SmithKline & French. Dr. Hallam received a BSc (Hons) in Biochemistry from the University of Leeds and a Ph.D. in Biochemistry from Kings College, University of London. He then conducted post-doctoral training at the Physiological Laboratory, University of Cambridge with Dr Tim Rink.

Job Titles:

• Chief Technical Operations Officer

Venkatesh Srinivasan, Ph.D. has served as our Chief Technical Operations Officer since May 2023. From April 2022 to May 2023, Dr. Srinivasan served as our Senior Vice President, Process, Analytical and Formulation Development. Prior to that, from March 2011 to March 2022, Dr. Srinivasan worked at Bayer AG, where he was most recently, the Vice President of Global Manufacturing Sciences and Technology. Dr. Srinivasan also co-founded GlycoRx Partners, LLC, a company focused on developing novel, half-life extended pharmaceutical proteins and peptides based on a unique glycoengineering platform, where he was a partner from 2009 to 2011. Prior to that, Dr. Srinivasan worked for Phyton Biotech, LLC where he served as Senior Director, Bioprocess Development and Director, Business Development. Dr. Srinivasan received his B.S. in Chemical Engineering from Indian Institute of Technology, Chennai, and his Ph.D. in Chemical Engineering from the State University of New York. He also held post-doctoral appointments at the School of Engineering, Cornell University, and at the Antibody Engineering Laboratory, University of California, Davis.

Job Titles:

• Chief Executive Officer
• Chief Executive Officer & Member, Board of Directors
• Chief Executive Officer and a Member

William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. Mr. Newell has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of Social Capital Suvretta Holdings Corp IV (NASDAQ: DNAD), Biotechnology Innovation Organization's (BIO) Health Section, Emerging Company Section and is a member of BIO's executive committee. He is member of California Life Science's (CLS) executive committee and previously served on CLS's board of directors. Mr. Newell received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School.